Merck & Co (MSD) and Eisai are set to discontinue their Phase III clinical trial for unresectable, non‑metastatic ...

Merck & Co (MSD) has taken the first of two possible plunges in its ongoing collaboration with Evaxion, gaining the rights to a mystery infectious disease vaccine candidate. The US big pharma decided ...

The company will expand its production facilities in Carlow and Cork to meet increased global demand for its medicines and vaccines produced in Ireland. MSD, known as Merck in the US and Canada, ...

MSD has agreed to purchase Takeda’s state-of-the art biologics plant in Meath and hopes to retain the site’s 200 employees. On Friday (7 August), MSD announced plans to acquire the Takeda ...

MSD has received US Food and Drug Administration (FDA) approval for an updated indication of Winrevair (sotatercept-csrk) for ...

COPENHAGEN - Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage TechBio company, has entered into an option and license agreement with pharmaceutical giant MSD, known as Merck & Co., Inc. in the U.S ...

MSD's Gardasil®9, a nine-valent HPV vaccine, is approved for use in males between 16 and 26 years old by China's National Medical Products Administration on Monday. [Photo provided to ...

MSD’s live attenuated quadrivalent vaccine is intended to be administered in one dose. Credit: Tada Images / Shutterstock. Merck & Co (MSD) has initiated the randomised MOBILIZE-1 Phase III trial to ...

- ATG-022 is Antengene's CLDN18.2 antibody-drug conjugate; KEYTRUDA ® (pembrolizumab) is MSD's anti-PD-1 therapy. ATG-022 is uniquely positioned in the global landscape, with data supporting ...

Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, getting a green light in China for sacituzumab tirumotecan (sac-TMT). The ...

The Philippines remains at risk for vaccine-preventable diseases, underscoring the need to increase vaccination coverage in the new normal. Based on joint monitoring by the World Health Organization ...